| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fast Track |
Division of Renal Diseases and Hypertension, University of Colorado Health Sciences Center, Denver, Colorado
Address correspondence to: Dr. Charles L. Edelstein, Division of Renal Diseases and Hypertension, University of Colorado School of Medicine, Box C281, 4200 E. 9th Avenue, Denver, CO 80262. Phone: 303-315-8764; Fax: 303-315-4852; E-mail: Charles.edelstein{at}uchsc.edu
Increased tubular epithelial cell proliferation is a prerequisite for cyst formation and expansion in polycystic kidney disease (PKD). Rapamycin is a potent antiproliferative agent. The aim of the present study was to determine the effect of rapamycin on tubular cell proliferation, cyst formation, and renal failure in the Han:SPRD rat model of PKD. Heterozygous (Cy/+) and littermate control (+/+) male rats were weaned at 3 wk of age and then treated with rapamycin 0.2 mg/kg per d intraperitoneally or vehicle (ethanol) for 5 wk. Vehicle-treated Cy/+ rats had a more than doubling of kidney size compared with +/+ rats. Rapamycin reduced the kidney enlargement by 65%. Rapamycin significantly reduced the cyst volume density in Cy/+ rats by >40%. Blood urea nitrogen was 59% increased in vehicle-treated Cy/+ rats compared with +/+ rats. Rapamycin reduced the blood urea nitrogen to normal in Cy/+ rats. The number of proliferating cell nuclear antigen (PCNA)-positive cells per noncystic tubule was eightfold increased in vehicle-treated Cy/+ compared with +/+ rats. Rapamycin significantly reduced the number of PCNA-positive cells in noncystic tubules of Cy/+ rats. In addition, the number of PCNA-positive cells per cyst in Cy/+ rats was significantly reduced by rapamycin. In summary, in a rat model of PKD, rapamycin treatment (1) decreases proliferation in cystic and noncystic tubules, (2) markedly inhibits renal enlargement and cystogenesis, and (3) prevents the loss of kidney function.
This article has been cited by other articles:
![]() |
L. Battini, S. Macip, E. Fedorova, S. Dikman, S. Somlo, C. Montagna, and G. L. Gusella Loss of polycystin-1 causes centrosome amplification and genomic instability Hum. Mol. Genet., September 15, 2008; 17(18): 2819 - 2833. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Leuenroth, N. Bencivenga, P. Igarashi, S. Somlo, and C. M. Crews Triptolide Reduces Cystogenesis in a Model of ADPKD J. Am. Soc. Nephrol., September 1, 2008; 19(9): 1659 - 1662. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Edelstein Mammalian Target of Rapamycin and Caspase Inhibitors in Polycystic Kidney Disease Clin. J. Am. Soc. Nephrol., July 1, 2008; 3(4): 1219 - 1226. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Tao, I. Zafar, J. Kim, R. W. Schrier, and C. L. Edelstein Caspase-3 Gene Deletion Prolongs Survival in Polycystic Kidney Disease J. Am. Soc. Nephrol., April 1, 2008; 19(4): 749 - 755. [Full Text] [PDF] |
||||
![]() |
C. C. Berthier, P. R. Wahl, M. L. Hir, H.-P. Marti, U. Wagner, H. Rehrauer, R. P. Wuthrich, and A. L. Serra Sirolimus ameliorates the enhanced expression of metalloproteinases in a rat model of autosomal dominant polycystic kidney disease Nephrol. Dial. Transplant., March 1, 2008; 23(3): 880 - 889. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Qian, H. Du, B. F. King, S. Kumar, P. G. Dean, F. G. Cosio, and V. E. Torres Sirolimus Reduces Polycystic Liver Volume in ADPKD Patients J. Am. Soc. Nephrol., March 1, 2008; 19(3): 631 - 638. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kramer, Y. Wang-Rosenke, V. Scholl, E. Binder, T. Loof, D. Khadzhynov, H. Kawachi, F. Shimizu, F. Diekmann, K. Budde, et al. Low-dose mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat Am J Physiol Renal Physiol, February 1, 2008; 294(2): F440 - F449. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Baba, M. Furihata, S.-B. Hong, L. Tessarollo, D. C. Haines, E. Southon, V. Patel, P. Igarashi, W. G. Alvord, R. Leighty, et al. Kidney-Targeted Birt-Hogg-Dube Gene Inactivation in a Mouse Model: Erk1/2 and Akt-mTOR Activation, Cell Hyperproliferation, and Polycystic Kidneys J Natl Cancer Inst, January 16, 2008; 100(2): 140 - 154. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Ibraghimov-Beskrovnaya Molecular pathogenesis of ADPKD and development of targeted therapeutic options Nephrol. Dial. Transplant., December 1, 2007; 22(12): 3367 - 3370. [Full Text] [PDF] |
||||
![]() |
K. Sataranatarajan, M. M. Mariappan, M. J. Lee, D. Feliers, G. G. Choudhury, J. L. Barnes, and B. S. Kasinath Regulation of Elongation Phase of mRNA Translation in Diabetic Nephropathy: Amelioration by Rapamycin Am. J. Pathol., December 1, 2007; 171(6): 1733 - 1742. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Weimbs Polycystic kidney disease and renal injury repair: common pathways, fluid flow, and the function of polycystin-1 Am J Physiol Renal Physiol, November 1, 2007; 293(5): F1423 - F1432. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. W. Kuehn and G. Walz Prime time for polycystic kidney disease: does one shot of roscovitine bring the cure? Nephrol. Dial. Transplant., August 1, 2007; 22(8): 2133 - 2135. [Full Text] [PDF] |
||||
![]() |
A. Schwarz, S. Vatandaslar, S. Merkel, and H. Haller Renal Cell Carcinoma in Transplant Recipients with Acquired Cystic Kidney Disease Clin. J. Am. Soc. Nephrol., July 1, 2007; 2(4): 750 - 756. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. R. Amura, K. S. Brodsky, R. Groff, V. H. Gattone, N. F. Voelkel, and R. B. Doctor VEGF receptor inhibition blocks liver cyst growth in pkd2(WS25/-) mice Am J Physiol Cell Physiol, July 1, 2007; 293(1): C419 - C428. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. B. Chapman Autosomal Dominant Polycystic Kidney Disease: Time for a Change? J. Am. Soc. Nephrol., May 1, 2007; 18(5): 1399 - 1407. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Leuenroth, D. Okuhara, J. D. Shotwell, G. S. Markowitz, Z. Yu, S. Somlo, and C. M. Crews Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease PNAS, March 13, 2007; 104(11): 4389 - 4394. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. M. Bernhardt, M. S. Wiesener, A. Weidemann, R. Schmitt, W. Weichert, P. Lechler, V. Campean, A. C. M. Ong, C. Willam, N. Gretz, et al. Involvement of Hypoxia-Inducible Transcription Factors in Polycystic Kidney Disease Am. J. Pathol., March 1, 2007; 170(3): 830 - 842. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. S. Kasinath, M. M. Mariappan, K. Sataranatarajan, M. J. Lee, and D. Feliers mRNA Translation: Unexplored Territory in Renal Science J. Am. Soc. Nephrol., December 1, 2006; 17(12): 3281 - 3292. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Zhang, J. Li, L. H. Young, and M. J. Caplan AMP-activated protein kinase regulates the assembly of epithelial tight junctions PNAS, November 14, 2006; 103(46): 17272 - 17277. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. R Lawson, T. W Doulton, and G. A MacGregor Review: Autosomal Dominant Polycystic Kidney Disease: Role of the Renin-Angiotensin System in Raised Blood Pressure in Progression of Renal and Cardiovascular Disease Journal of Renin-Angiotensin-Aldosterone System, September 1, 2006; 7(3): 139 - 145. [Abstract] [PDF] |
||||
![]() |
M. Y. Chang, E. Parker, S. Ibrahim, J. R. Shortland, M. E. Nahas, J. L. Haylor, and A. C. M. Ong Haploinsufficiency of Pkd2 is associated with increased tubular cell proliferation and interstitial fibrosis in two murine Pkd2 models Nephrol. Dial. Transplant., August 1, 2006; 21(8): 2078 - 2084. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. E. Torres Water for ADPKD? Probably, Yes J. Am. Soc. Nephrol., August 1, 2006; 17(8): 2089 - 2091. [Full Text] [PDF] |
||||
![]() |
G. Walz Therapeutic approaches in autosomal dominant polycystic kidney disease (ADPKD): is there light at the end of the tunnel? Nephrol. Dial. Transplant., July 1, 2006; 21(7): 1752 - 1757. [Full Text] [PDF] |
||||
![]() |
J. J. Grantham, V. E. Torres, A. B. Chapman, L. M. Guay-Woodford, K. T. Bae, B. F. King Jr., L. H. Wetzel, D. A. Baumgarten, P. J. Kenney, P. C. Harris, et al. Volume Progression in Polycystic Kidney Disease N. Engl. J. Med., May 18, 2006; 354(20): 2122 - 2130. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Lloberas, J. M. Cruzado, M. Franquesa, I. Herrero-Fresneda, J. Torras, G. Alperovich, I. Rama, A. Vidal, and J. M. Grinyo Mammalian Target of Rapamycin Pathway Blockade Slows Progression of Diabetic Kidney Disease in Rats J. Am. Soc. Nephrol., May 1, 2006; 17(5): 1395 - 1404. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Shillingford, N. S. Murcia, C. H. Larson, S. H. Low, R. Hedgepeth, N. Brown, C. A. Flask, A. C. Novick, D. A. Goldfarb, A. Kramer-Zucker, et al. From the Cover: The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease PNAS, April 4, 2006; 103(14): 5466 - 5471. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. R. Wahl, A. L. Serra, M. Le Hir, K. D. Molle, M. N. Hall, and R. P. Wuthrich Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD) Nephrol. Dial. Transplant., March 1, 2006; 21(3): 598 - 604. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. G.B. Bonegio, R. Fuhro, Z. Wang, C. R. Valeri, C. Andry, D. J. Salant, and W. Lieberthal Rapamycin Ameliorates Proteinuria-Associated Tubulointerstitial Inflammation and Fibrosis in Experimental Membranous Nephropathy J. Am. Soc. Nephrol., July 1, 2005; 16(7): 2063 - 2072. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Tao, J. Kim, S. Faubel, J. C. Wu, S. A. Falk, R. W. Schrier, and C. L. Edelstein Caspase inhibition reduces tubular apoptosis and proliferation and slows disease progression in polycystic kidney disease PNAS, May 10, 2005; 102(19): 6954 - 6959. [Abstract] [Full Text] [PDF] |
||||
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |
Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673